According to a The Street: Real Money article, 2018 has been the year of IPOs in the cannabis space. So far, MedMen (CSE:MMEN), Green Organic Dutchman (TSE:TGOD) and Tilray (NASDAQ:THRY) have gone public with varying results. MedMen’s IPO did not go at the start, but has been slowly making its way higher in the charts, while the Green Organic Dutchman started out strong only to stumble later and is slowly gaining some traction in the market again. Tilray has been the only cannabis stock that has been consistently doing well since it’s IPO. Tilray has been able to make 95 percent more than it did last year in its second quarter and its stocked jumped 10 percent on Tuesday this week after the company announced its results.
The article discussed the cannabis companies with IPOs that have been causing a lot of talk in the market place, the Flowr Corporation is one of those companies. Flowr intends to “list its shares on the TSX Ventures Exchange” within the first couple of weeks in September. Flowr has agreements in place with the British Columbia Liquor Distribution Board, which is the sole retailer of recreational cannabis post-legalization in October and Flowr’s research and development agreement with Scotts Miracle-Gro subsidiary Hawthorne Gardening Company.
The article highlighted four additional cannabis companies that are looking to list by the end of the year. The companies include Acreage Holdings, a vertically-integrated cannabis investment company; Curaleaf, a holding company that specializes in the medical cannabis industry; Canopy Rivers, a spin off from its parent company Canopy Growth (TSE:WEED); and Charlotte’s Web, a high-quality hemp producer.
To read the full article, click here.
Subsequent to this press release, The Flowr Corporation went public on September 26, 2018 under the ticker symbol TSXV:FLWR.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.